In Vivo 2012-01-01

Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine.

Leonard Amaral, Joseph Molnar

Index: In Vivo 26(2) , 231-6, (2012)

Full Text: HTML

Abstract

Multidrug-resistant tuberculosis (MDRTB) infections that continue to increase in frequency globally have progressed to become extremely drug-resistant tuberculosis (XDRTB). The therapeutic problems associated with MDRTB pale in comparison to those for XDRTB where mortality is high. This mini-review highlights the evidence that supports the use of the phenothiazine neuroleptic thioridazine for the therapy of XDRTB. Although thioridazine does produce some serious side-effects, the poor prognosis associated with an XDRTB infection of a patient that presents with AIDS merits that the use of thioridazine for therapy of XDRTB is seriously considered. A recommended protocol is presented.